Dominion Energy Inc vs BIO-TECHNE Corp — how do they compare? Dominion Energy Inc trades at $61.75 (market cap $54.12B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Dominion Energy Inc is far larger — about 4.8× BIO-TECHNE Corp's market cap, and Dominion Energy Inc pays the higher dividend (4.34%). Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and BIO-TECHNE Corp for 63 Days on average.
| D | TECH | |
|---|---|---|
Market Cap | $54.12B | $11.37B |
Volume | 4,249,753 | 3,153,511 |
Sector | Utilities | Health |
52-Week High | $71.67 | $72.61 |
52-Week Low | $57.08 | $43.31 |
Typical Hold Time | 76 Days | 63 Days |
Enterprise Value | $108.24B | $11.40B |
Dividend Yield | 4.34% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.75, down 0.4% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 EPS of $0.79 versus $0.681 expected, continuing a pattern of exceeding expectations. Fundamentals show improving revenue growth to $16.51B in 2025 and net income margin expansion to 13.99%, though cash flow trends show significant capital investments. The pending merger with NextEra Energy dominates recent news coverage, with regulators reviewing a proposed $1 billion annual Virginia supplier program.
Dominion Energy presents a mixed investment case with solid fundamental performance offset by technical weakness and merger execution risks. The stock trades below analyst consensus target of $71.56, offering potential upside if the NextEra merger proceeds smoothly. Key risks include regulatory approval uncertainty, high capital expenditure requirements, and interest rate sensitivity given the company's substantial debt load of $37.31B long-term.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
Latest headlines on both assets
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →